Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Last updated: November 7, 2024
Sponsor: Insel Gruppe AG, University Hospital Bern
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sleep Disorders

Parkinson's Disease

Lewy Body Dementia

Treatment

MRI

SPECT : 123 I-FP-CIT (DATSCAN)

PET/CT with 18-FDG

Clinical Study ID

NCT06629207
2023-00816
  • Ages > 18
  • All Genders

Study Summary

The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to theInternational Classification of Sleep Disorders

  2. Written informed consent

Exclusion

Exclusion Criteria:

  1. Known diagnosis of PD or other neurodegenerative disorder

  2. Unequivocal signs of parkinsonism on examination

  3. Narcolepsy or other known causes of RBD

  4. Moderate to severe obstructive sleep apnea

  5. Abnormal neurological or MRI examination

Study Design

Total Participants: 20
Treatment Group(s): 3
Primary Treatment: MRI
Phase:
Study Start date:
October 07, 2024
Estimated Completion Date:
August 01, 2026

Connect with a study center

  • Inselspital, University Clinic for Nuclear Medicine

    Bern, 3010
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.